Characteristics of risk factors for dementia in women: a possible preventive role of menopausal hormone therapy

1. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4): 459-509.

2. Lehert P., Villaseca P., Hogervorst E., Maki P.M., Henderson V.W. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. Climacteric. 2015; 18(5): 678-89.

3. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013; 9(2): 106-18.

4. Neu S.C., Pa J., Kukull W., Beekly D., Kuzma A., Gangadharan P. et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease. A meta-analysis. JAMA Neurol. 2017; 74(10): 1178-89.

5. Gottesman R.F., Albert M.S., Alonso A., Coker L.H., Coresh J., Davis S.M. et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017; 74(10): 1246-54.

6. Gottesman R.F., Schneider A.L., Zhou Y., Coresh J., Green E., Gupta N. et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017; 317(15): 1443-50.

7. Gottesman R.F., Schneider A.L., Albert M., Alonso A., Bandeen-Roche K., Coker L. et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 2014; 71(10): 1218-27.

8. Debette S., Seshadri S., Beiser A., Au R., Himali J.J., Palumbo C. et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011; 77(5): 461-8.

9. Thurston R.C., Aizenstein H.J., Derby C.A., Sejdić E., Maki P.M. Menopausal hot flashes and white matter hyperintensities. Menopause. 2016; 23(1): 27-32.

10. Song J., Lee W.T., Park K.A., Lee J.E. Association between risk factors for vascular dementia and adiponectin. Biomed. Res. Int. 2014; 2014: 261672.

11. Abdulnour J., Doucet E., Brochu M., Lavoie J.M., Strychar I., Rabasa-Lhoret R., Prud'homme D. The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause. 2012; 19(7): 760-7.

12. Willette A.A., Bendlin B.B., Starks E.J., Birdsill A.C., Johnson S.C., Christian B.T. et al. Association of insulin resistance with cerebral glucose uptake in late middle - aged adults at risk for Alzheimer disease. JAMA Neurol. 2015; 72(9): 1013-20.

13. Mitchell E.S., Woods N.F. Cognitive symptoms during the menopausal transition and early postmenopause. Climacteric. 2011; 14(2): 252-61.

14. Epperson C.N., Sammel M.D., Freeman E.W. Menopause effects on verbal memory: findings from a longitudinal community cohort. J. Clin. Endocrinol. Metab. 2013; 98(9): 3829-38.

15. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95.

16. Weber M.T., Rubin L.H., Maki P.M. Cognition in perimenopause: The effect of transition stage. Menopause. 2013; 20(5): 511-7.

17. Karlamangla A.S., Lachman M.E., Han W., Huang M., Greendale G.A. Evidence for cognitive aging in midlife women: study of women’s health across the nation. PLoS One. 2017; 12(1): e0169008

18. Brinton R.D., Yao J., Yin F., Mack W.J., Cadenas E. Perimenopause as a neurological transition state. Nat. Rev. Endocrinol. 2015; 11(7): 393-405.

19. Singh M., Su C. Progesterone and neuroprotection. Horm. Behav. 2013; 63(2):284-90.

20. Schumacher M., Hussain R., Gago N., Oudinet J.P., Mattern C., Ghoumari A.M. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front. Neurosci. 2012; 6: 10.

21. Sitruk-Ware R., El-Etr M. Progesterone and related progestins: potential new health benefits. Climacteric. 2013; 16(Suppl. 1): 69-78.

22. Sperling R.A., Karlawish J., Johnson K.A. Preclinical Alzheimer disease - the challenges ahead. Nat. Rev. Neurol. 2013; 9(1): 54-8.

23. Gleason C.E., Dowling N.M., Wharton W., Manson J.E., Miller V.M., Atwood C.S. et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015; 12(6): e1001833.

24. Henderson V.W., St John J.A., Hodis H.N., McCleary C.A., Stanczyk F.Z., Shoupe D. et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology. 2016; 87(7): 699-708.

25. Imtiaz B., Tuppurainen M., Rikkonen T., Kivipelto M., Soininen H., Kröger H., Tolppanen A.M. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology. 2017; 88(11): 1062-8.

26. Shao H., Breitner J.C., Whitmer R.A., Wang J., Hayden K., Wengreen H. et al.; Cache County Investigators. Hormone therapy and AD dementia: new findings from the Cache County study. Neurology. 2012; 79(18): 1846-52.

27. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68.

28. Matsui S., Yasui T., Tani A., Kato T., Kunimi K., Uemura H. et al. Association of circulating adiponectin with testosterone in women during the menopausal transition. Maturitas. 2012; 73(3): 255-60.

29. Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016; 19(4): 349-56.

30. Davison S.L., Bell R.J., Robinson P.J., Jane F., Leech J., Maruff P. et al. Continuous combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo controlled trial. Menopause. 2013; 20(10): 1020-6.

31. Селедцова Н.В., Овсянникова Т.В. Эффективность и безопасность применения комбинации 17β-эстрадиол/дроспиренон для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома. Медицинский совет. 2016; 17: 120-3. [Seledtsova N.V., Ovsyannikova Т.V. Efficacy and safety of the use of the 17β-estradiol/drospirenone combination for menopausal hormone therapy in patients at risk of metabolic syndrome. Meditsinskiy sovet. 2016; 17: 120-3. (in Russian)]

32. Mikkola T.S., Savolainen-Peltonen H., Tuomikoski P., Hoti F., Vattulainen P., Gissler M., Ylikorkala O. Lower death risk for vascular dementia than for Alzheimer’s disease with postmenopausal hormone therapy users. J. Clin. Endocrinol. Metab. 2017; 102(3): 870-7.

33. Baber R.J., Panay N., Fenton A. and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.

34. Gass M.L., Maki P.M., Shifren J.L., Schnatz P.F., Kaunitz A.M., Shapiro M., Sievert L.L. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685-6.

35. Practice Bulletin ACOG No. 141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16.

36. Yao J., Irwin R., Chen S., Hamilton R., Cadenas E., Brinton R.D. Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid. Neurobiol. Aging. 2012; 33(8): 1507-21.

Received 16.02.2018

Accepted 02.03.2018